|
Gene: PNP |
Gene summary for PNP |
Gene summary. |
Gene information | Species | Human | Gene symbol | PNP | Gene ID | 4860 |
Gene name | purine nucleoside phosphorylase | |
Gene Alias | NP | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000255 | UniProtAcc | P00491 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4860 | PNP | LZE5T | Human | Esophagus | ESCC | 2.61e-04 | -2.12e-01 | 0.0514 |
4860 | PNP | LZE7T | Human | Esophagus | ESCC | 1.30e-04 | 4.39e-02 | 0.0667 |
4860 | PNP | LZE8T | Human | Esophagus | ESCC | 3.72e-02 | -1.81e-01 | 0.067 |
4860 | PNP | LZE20T | Human | Esophagus | ESCC | 4.33e-05 | -6.62e-02 | 0.0662 |
4860 | PNP | LZE22D1 | Human | Esophagus | HGIN | 8.91e-05 | -3.66e-01 | 0.0595 |
4860 | PNP | P2T-E | Human | Esophagus | ESCC | 3.23e-05 | 3.00e-01 | 0.1177 |
4860 | PNP | P4T-E | Human | Esophagus | ESCC | 2.76e-14 | 9.17e-01 | 0.1323 |
4860 | PNP | P5T-E | Human | Esophagus | ESCC | 7.78e-13 | 6.22e-01 | 0.1327 |
4860 | PNP | P8T-E | Human | Esophagus | ESCC | 2.62e-05 | -7.14e-02 | 0.0889 |
4860 | PNP | P10T-E | Human | Esophagus | ESCC | 8.64e-04 | -2.14e-01 | 0.116 |
4860 | PNP | P11T-E | Human | Esophagus | ESCC | 2.32e-08 | 1.17e+00 | 0.1426 |
4860 | PNP | P12T-E | Human | Esophagus | ESCC | 1.55e-04 | 2.69e-01 | 0.1122 |
4860 | PNP | P15T-E | Human | Esophagus | ESCC | 7.28e-14 | 7.41e-01 | 0.1149 |
4860 | PNP | P16T-E | Human | Esophagus | ESCC | 3.18e-05 | 7.02e-02 | 0.1153 |
4860 | PNP | P21T-E | Human | Esophagus | ESCC | 3.63e-14 | 4.45e-01 | 0.1617 |
4860 | PNP | P22T-E | Human | Esophagus | ESCC | 7.28e-03 | 1.98e-01 | 0.1236 |
4860 | PNP | P23T-E | Human | Esophagus | ESCC | 5.50e-03 | 3.36e-01 | 0.108 |
4860 | PNP | P24T-E | Human | Esophagus | ESCC | 4.31e-03 | 2.39e-01 | 0.1287 |
4860 | PNP | P26T-E | Human | Esophagus | ESCC | 1.67e-07 | 4.57e-01 | 0.1276 |
4860 | PNP | P27T-E | Human | Esophagus | ESCC | 1.88e-11 | 5.75e-01 | 0.1055 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006115718 | Skin | cSCC | mRNA destabilization | 44/4864 | 84/18723 | 2.14e-07 | 4.60e-06 | 44 |
GO:006101418 | Skin | cSCC | positive regulation of mRNA catabolic process | 45/4864 | 87/18723 | 2.53e-07 | 5.29e-06 | 45 |
GO:0019693112 | Skin | cSCC | ribose phosphate metabolic process | 146/4864 | 396/18723 | 9.28e-07 | 1.68e-05 | 146 |
GO:005077918 | Skin | cSCC | RNA destabilization | 44/4864 | 88/18723 | 1.16e-06 | 2.03e-05 | 44 |
GO:00311244 | Skin | cSCC | mRNA 3'-end processing | 34/4864 | 62/18723 | 1.27e-06 | 2.20e-05 | 34 |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:000756827 | Skin | cSCC | aging | 127/4864 | 339/18723 | 1.80e-06 | 3.02e-05 | 127 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:004343426 | Skin | cSCC | response to peptide hormone | 150/4864 | 414/18723 | 2.11e-06 | 3.43e-05 | 150 |
GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
GO:00063784 | Skin | cSCC | mRNA polyadenylation | 26/4864 | 44/18723 | 3.48e-06 | 5.29e-05 | 26 |
GO:00436314 | Skin | cSCC | RNA polyadenylation | 26/4864 | 45/18723 | 6.20e-06 | 8.78e-05 | 26 |
GO:003424915 | Skin | cSCC | negative regulation of cellular amide metabolic process | 104/4864 | 273/18723 | 6.44e-06 | 9.00e-05 | 104 |
GO:0009259112 | Skin | cSCC | ribonucleotide metabolic process | 138/4864 | 385/18723 | 1.00e-05 | 1.30e-04 | 138 |
GO:003109924 | Skin | cSCC | regeneration | 79/4864 | 198/18723 | 1.18e-05 | 1.51e-04 | 79 |
GO:000912610 | Skin | cSCC | purine nucleoside monophosphate metabolic process | 25/4864 | 44/18723 | 1.40e-05 | 1.74e-04 | 25 |
GO:00091235 | Skin | cSCC | nucleoside monophosphate metabolic process | 37/4864 | 76/18723 | 1.75e-05 | 2.11e-04 | 37 |
GO:0006163112 | Skin | cSCC | purine nucleotide metabolic process | 140/4864 | 396/18723 | 1.93e-05 | 2.27e-04 | 140 |
GO:001714814 | Skin | cSCC | negative regulation of translation | 93/4864 | 245/18723 | 2.28e-05 | 2.63e-04 | 93 |
GO:0009150112 | Skin | cSCC | purine ribonucleotide metabolic process | 131/4864 | 368/18723 | 2.42e-05 | 2.76e-04 | 131 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PNP | SNV | Missense_Mutation | novel | c.416N>T | p.Pro139Leu | p.P139L | P00491 | protein_coding | tolerated(0.53) | benign(0.298) | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
PNP | insertion | Nonsense_Mutation | novel | c.801_802insCCCCTTGTTCAGTAGCCTCTTCTTTAAGAA | p.Ala267_Ala268insProLeuValGlnTerProLeuLeuTerGlu | p.A267_A268insPLVQ*PLL*E | P00491 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PNP | deletion | Frame_Shift_Del | novel | c.134delN | p.Gln46ArgfsTer28 | p.Q46Rfs*28 | P00491 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
PNP | SNV | Missense_Mutation | novel | c.611C>T | p.Ala204Val | p.A204V | P00491 | protein_coding | deleterious(0) | benign(0.158) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PNP | SNV | Missense_Mutation | rs150531909 | c.482N>T | p.Ala161Val | p.A161V | P00491 | protein_coding | tolerated(0.07) | benign(0.183) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PNP | SNV | Missense_Mutation | c.839N>T | p.Ala280Val | p.A280V | P00491 | protein_coding | tolerated(0.16) | benign(0.012) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PNP | SNV | Missense_Mutation | rs755640590 | c.646N>A | p.Ala216Thr | p.A216T | P00491 | protein_coding | deleterious(0.05) | probably_damaging(0.914) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PNP | SNV | Missense_Mutation | novel | c.71N>A | p.Arg24Gln | p.R24Q | P00491 | protein_coding | tolerated(0.06) | benign(0.021) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PNP | SNV | Missense_Mutation | rs769652649 | c.472N>T | p.Arg158Cys | p.R158C | P00491 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PNP | SNV | Missense_Mutation | novel | c.819N>T | p.Gln273His | p.Q273H | P00491 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4860 | PNP | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL550755 | FORODESINE HYDROCHLORIDE | |
4860 | PNP | ENZYME, DRUGGABLE GENOME | Guanosine | GUANOSINE | ||
4860 | PNP | ENZYME, DRUGGABLE GENOME | ULODESINE | ULODESINE | ||
4860 | PNP | ENZYME, DRUGGABLE GENOME | FORODESINE | FORODESINE | ||
4860 | PNP | ENZYME, DRUGGABLE GENOME | BCX-3408 | ULODESINE | ||
4860 | PNP | ENZYME, DRUGGABLE GENOME | 2'3'-Dideoxyinosine | |||
4860 | PNP | ENZYME, DRUGGABLE GENOME | FORODESINE HYDROCHLORIDE | FORODESINE HYDROCHLORIDE | 19386496,19386498 | |
4860 | PNP | ENZYME, DRUGGABLE GENOME | Peldesine | PELDESINE | ||
4860 | PNP | ENZYME, DRUGGABLE GENOME | inhibitor | 252166484 | FORODESINE | |
4860 | PNP | ENZYME, DRUGGABLE GENOME | Forodesine | FORODESINE |
Page: 1 |